ProfileGDS5678 / 1427816_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 77% 77% 75% 77% 84% 81% 80% 82% 80% 80% 80% 78% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4354379
GSM967853U87-EV human glioblastoma xenograft - Control 25.3400177
GSM967854U87-EV human glioblastoma xenograft - Control 35.1855577
GSM967855U87-EV human glioblastoma xenograft - Control 45.1481775
GSM967856U87-EV human glioblastoma xenograft - Control 55.2240177
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9702684
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5989181
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6699680
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8727482
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6400180
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6741380
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6774480
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3331978
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0719383